VXRT - Vaxart Inc logo

VXRT

Vaxart Inc

Rev 272xtop 1%5Y
Hold

Vaxart Inc. develops oral recombinant protein vaccines using its proprietary platform. Its pipeline includes vaccines for norovirus, COVID-19, seasonal influenza, and human papillomavirus, targeting various viral strains and diseases.

โš•๏ธ Healthcare NASDAQ Listed 2018 $ USD
$1,000 invested 30 years ago โ†’$1today

Score Overview

1 Year
Score
Net Growth136.35%
Net TrendGrew
Net Income Consistencyโ€”
Rev Growth2.45%
Rev TrendGrew
Revenue Consistencyโ€”
5 Years
Score7.6
Net Growth154.76%
Net Trend80%
Net Income Consistencyโ€”
Rev Growth272x
Rev Trend80%
Revenue Consistencyโ€”
All Time
Score
Net Growth314.30%
Net Trend50%
Net Income Consistency
Rev Growth58x
Rev Trend63%
Revenue Consistency

See the full market ranking โ†’

Vaxart Inc fundamental performance

Between 2020 and 2025, revenue grew from $ 4M to $ 237M and net income went from -$ 32M to $ 16M. Revenue increased in 4 of those 5 years; net income in 4.

Vaxart Inc currently holds a 5-year HDB Score of 7.6 out of 10. How the HDB Score is calculated.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-08-12
$ 0.57โ€”
1 Year2025-08-12
$ 0.3849.97%
5 Years2021-08-12
$ 9.13-93.76%
10 Years2016-08-12
$ 14.85-96.16%
20 Years2006-08-11
$ 289.04-99.80%
30 Years1996-08-12
$ 562.67-99.90%
All Time2018-02-12
$ 8.80-93.52%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Year
2026$ 243M$ 38M$ 63M
2025$ 237M$ 16M$ 63M
2024$ 28M-$ 66M$ 51M
2023$ 7M-$ 82M$ 39M
2022$ 107K-$ 107M$ 93M
2021$ 892K-$ 70M$ 166M
2020$ 4M-$ 32M$ 126M
2019$ 9M-$ 18M$ 13M
IPO2018$ 4M-$ 18M$ 11M

Explore beyond VXRT

You're looking at Vaxart Inc. Members apply the same fundamental framework across all 3,860 companies we cover.

$99/year $149 founding price

Unlock Holder Dashboard

30-day money-back guarantee.

Explore other companies